PORTFOLIO NEWS Revolution Medicines Reports Fourth Quarter and Year-End 2020 Financial Results and Update on Corporate Progress March 2, 2021 Read More » NGM Bio Initiates Expansion of Ongoing Phase 1b Proof-of-Concept Study of NGM120 in Patients with Metastatic Pancreatic Cancer March 2, 2021 Read More » Tenaya Therapeutics Secures $106 Million in Series C Funding to Accelerate Pipeline of Potentially Curative Therapies for Heart Disease March 1, 2021 Read More » Constellation Pharmaceuticals Announces Fourth-Quarter and Full-Year 2020 Financial Results February 24, 2021 Read More » Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2020 Financial Results and Provides a Corporate Update February 16, 2021 Read More » Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares February 8, 2021 Read More » Ribon Therapeutics Announces License Agreement with Ono Pharmaceutical Co., Ltd. to Develop and Commercialize RBN-2397 In Japan, South Korea, Taiwan and ASEAN Countries February 2, 2021 Read More » Plexium Announces $35m Financing to Advance Pipeline of Novel Protein Degraders January 21, 2021 Read More » NGM Bio Outlines 2021 Strategic Priorities Across Its Three Therapeutic Area Portfolios, Including Liver and Metabolic Diseases, Retinal Diseases and Oncology January 12, 2021 Read More » ORIC Pharmaceuticals Provides Corporate Update and Highlights Key 2021 Milestones January 11, 2021 Read More » « Previous Page1 Page2 Page3 Page4 Page5 Page6 Page7 Page8 Page9 Page10 Page11 Page12 Page13 Page14 Page15 Page16 Page17 Page18 Page19 Page20 Next »
Revolution Medicines Reports Fourth Quarter and Year-End 2020 Financial Results and Update on Corporate Progress March 2, 2021 Read More »
NGM Bio Initiates Expansion of Ongoing Phase 1b Proof-of-Concept Study of NGM120 in Patients with Metastatic Pancreatic Cancer March 2, 2021 Read More »
Tenaya Therapeutics Secures $106 Million in Series C Funding to Accelerate Pipeline of Potentially Curative Therapies for Heart Disease March 1, 2021 Read More »
Constellation Pharmaceuticals Announces Fourth-Quarter and Full-Year 2020 Financial Results February 24, 2021 Read More »
Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2020 Financial Results and Provides a Corporate Update February 16, 2021 Read More »
Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares February 8, 2021 Read More »
Ribon Therapeutics Announces License Agreement with Ono Pharmaceutical Co., Ltd. to Develop and Commercialize RBN-2397 In Japan, South Korea, Taiwan and ASEAN Countries February 2, 2021 Read More »
Plexium Announces $35m Financing to Advance Pipeline of Novel Protein Degraders January 21, 2021 Read More »
NGM Bio Outlines 2021 Strategic Priorities Across Its Three Therapeutic Area Portfolios, Including Liver and Metabolic Diseases, Retinal Diseases and Oncology January 12, 2021 Read More »
ORIC Pharmaceuticals Provides Corporate Update and Highlights Key 2021 Milestones January 11, 2021 Read More »
